WoundReference improves clinical decisions
 Choose the role that best describes you
Assaad NN, Chong R, Tat LT, Bennett MH, Coroneo MT, et al.
Cornea. Date of publication 2011 Jan 1;volume 30(1):7-10.
1. Cornea. 2011 Jan;30(1):7-10. doi: 10.1097/ICO.0b013e3181da58a4. Use of adjuvant hyperbaric oxygen therapy to support limbal conjunctival graft in the management of recurrent pterygium. Assaad NN(1), Chong R, Tat LT, Bennett MH, Coroneo MT. Author information: (1)Department of Ophthalmology, The University of New South Wales and Prince of Wales Hospital, Randwick, New South Wales, Australia. PURPOSE: To assess the role of hyperbaric oxygen therapy (HBOT) in the management of recurrent pterygium. METHODS: Thirty-nine eyes with recurrent pterygium were treated with surgical excision and limbal conjunctival autograft, followed by a course of HBOT. Patients were followed for development of recurrence. RESULTS: Of the 39 eyes, 18 had a known history of exposure to beta radiation or mitomycin C. The mean duration of follow-up in this group was 23.1 months. A single recurrence was noted in this group. For the remaining 21 eyes, the mean duration of follow-up was 19.4 months. No recurrences were recorded in this group. No significant complications from HBOT were recorded. CONCLUSIONS: The use of HBOT together with excision and limbal conjunctival autograft for recurrent pterygium is associated with a low recurrence rate. Adjuvant HBOT should be considered in the surgical management of recurrent pterygium. DOI: 10.1097/ICO.0b013e3181da58a4 PMID: 20847683 [Indexed for MEDLINE]
Appears in following Topics:
Compromised Skin Grafts and Flaps